Bank of New York Mellon’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Bank of New York Mellon’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-12,292	Closed	-$2K	–	4378
2016 Q3	$2K	Sell	12,292 -1,676	-12%	-$387	﹤0.01%	4263
2016 Q2	$4K	Sell	13,968 -18,228	-57%	-$5.07K	﹤0.01%	4313
2016 Q1	$5K	Buy	32,196 +18,578	+136%	+$5.16K	﹤0.01%	4210
2015 Q4	$24K	Sell	13,618 -108,065	-89%	-$190K	﹤0.01%	4263
2015 Q3	$226K	Buy	121,683 +108,065	+794%	+$257K	﹤0.01%	3864
2015 Q2	$32K	Buy	13,618 +1,550	+13%	+$4.78K	﹤0.01%	4197
2015 Q1	$53K	Buy	12,068 +2,068	+21%	+$10.4K	﹤0.01%	4138
2014 Q4	$48K	Buy	+10,000	New	+$44.7K	﹤0.01%	4150
2014 Q2	–	Sell	-36,604	Closed	-$234K	–	4301
2014 Q1	$234K	Sell	36,604 -12,203	-25%	-$110K	﹤0.01%	3809
2013 Q4	$465K	Buy	+48,807	New	+$381K	﹤0.01%	3606

Other funds holding TLOG

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BWA

Burt Wealth Advisors North Bethesda, Maryland $407M AUM 11.98% 1-Year Est. Return

Bank of New York Mellon's TLOG Position: Q4 2016 in Review

Bank of New York Mellon sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2016, closing a stake of 12,292 shares — an estimated $2K sold.

Bank of New York Mellon first reported a position in TLOG in Q4 2013 and held it in 10 quarters. The position peaked at $465K in Q4 2013. 3 funds tracked by Wall St. Rank hold TLOG as of Q4 2016.

Bank of New York Mellon reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2016 after selling out during the quarter.
Bank of New York Mellon sold 12,292 TetraLogic Pharmaceuticals Corporation shares in Q4 2016, an estimated $2K.
Bank of New York Mellon first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 10 quarters.
Bank of New York Mellon's TetraLogic Pharmaceuticals Corporation position peaked at $465K in Q4 2013.
3 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2016.

Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.